Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Smoldering Multiple Myeloma 3Pancreatic Neoplasms 2Multiple Myeloma 2Melanoma 2Triple Negative Breast Neoplasms 1PTEN-Altered Advanced Solid Tumors and HER2 Negative Breast Cancer 1Neuroendocrine Tumors 1Neoplasms 1Neoplasm Metastasis 1Myasthenia Gravis 1Multiple Endocrine Neoplasia 1Lung Neoplasms 1Hematologic Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1Breast Diseases 1Arthritis, Rheumatoid 1Acute Graft Versus Host Disease 1

Interventions

Rituximab 7Pyridostigmine Bromide 5Prednisone 5efgartigimod alfa 4Hizentra 4telitacicept 3Immunoglobulins, Intravenous 3Cyclophosphamide 3Azathioprine 3thymoglobulin 2fludarabine 2Thymectomy 2Steroids 2Mycophenolic Acid 2Data Collection 2Blood Specimen Collection 2zilucoplan 1tofacitinib 1tocilizumab 1talquetamab 1sargramostim 1rozanolixizumab 1prednylidene 1gamma-Globulins 1deltacortene 1carmustine, poliferprosan 20 drug combination 1bu-zhong-yi-qi-tang 1apraclonidine 1Walk Test 1Therapeutics 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Myasthenia Gravis × Leflunomide × Clear all
NCT01727193 2022-04-14

The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy

First Affiliated Hospital, Sun Yat-Sen University

Phase 3 Completed
290 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡